Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Monopar Therapeutics Inc (NQ: MNPR ) 0.7300 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EDT, Jul 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Monopar Therapeutics Inc < Previous 1 2 Next > Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr July 09, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24 June 25, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar and NorthStar Amend & Extend Collaboration June 11, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting June 10, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces CFO Succession May 24, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline May 09, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting April 18, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings April 16, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients April 10, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments March 28, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program March 05, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial February 27, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers February 22, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers February 20, 2024 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments November 09, 2023 MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual... From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting November 01, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference October 10, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments August 10, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Provides Encouraging Camsirubicin Clinical Data Update August 08, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore July 11, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar to Participate in the Radiopharma Forum by the Lake 2023 June 21, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference June 14, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update June 01, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments May 11, 2023 Camsirubicin Phase 1b DoseEscalation Trial Enrolling 5th DoseLevel Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results From Monopar Therapeutics Inc. Via GlobeNewswire Monopar to Present at the Jefferies Radiopharma Innovation Summit March 28, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis March 27, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments March 23, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar to Present at the 35th Annual Roth Conference March 07, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials February 27, 2023 From Monopar Therapeutics Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.